AR037528A1 - Derivados de piridona de benzotiazol - Google Patents
Derivados de piridona de benzotiazolInfo
- Publication number
- AR037528A1 AR037528A1 ARP020104398A ARP020104398A AR037528A1 AR 037528 A1 AR037528 A1 AR 037528A1 AR P020104398 A ARP020104398 A AR P020104398A AR P020104398 A ARP020104398 A AR P020104398A AR 037528 A1 AR037528 A1 AR 037528A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- lower alkyl
- alkyl
- compounds
- piridona
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 229940045200 cardioprotective agent Drugs 0.000 abstract 1
- 239000012659 cardioprotective agent Substances 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 229960004756 ethanol Drugs 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 229940035363 muscle relaxants Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- -1 opioids Chemical compound 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de fórmula general (1), en donde: R es fenilo, piridin-2-ilo, -C(O)-O-alquilo inferior, -C(O)-alquilo inferior, -C(O)-morfolinilo, -C(O)-NR'2, -(CH2)n-NR'2 ó -(CH2)n-O-alquilo inferior, y R' puede ser hidrógeno o alquilo inferior; y sales de adición farmacéutica aceptables de los mismos. Los compuestos descritos en la presente tienen una buena afinidad al receptor A2A y por lo tanto pueden emplearse en el control o prevención de enfermedades basadas en la modulación del sistema de la adenosina, tales como la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, neuroprotección, esquizofrenia, ansiedad, dolor, déficits respiratorios, depresión, adicción a las drogas, tales como la anfetamina, cocaína, opioides, etanol, nicotina, cannabinoides, o contra el asma, respuestas alérgicas, hipoxia, isquemia, ataques, y abuso de substancias. Además, los compuestos pueden ser de utilidad como sedantes, relajantes musculares, antipsicóticos, antiepilípticos, anticonvulsivos y agentes cardioprotectores para trastornos tales como la enfermedad de la arteria coronaria y fallo cardíaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01127313 | 2001-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037528A1 true AR037528A1 (es) | 2004-11-17 |
Family
ID=8179264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104398A AR037528A1 (es) | 2001-11-19 | 2002-11-15 | Derivados de piridona de benzotiazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6599901B1 (es) |
| EP (1) | EP1448196B1 (es) |
| JP (1) | JP4216192B2 (es) |
| KR (1) | KR100577109B1 (es) |
| CN (1) | CN100346792C (es) |
| AR (1) | AR037528A1 (es) |
| AT (1) | ATE306265T1 (es) |
| AU (1) | AU2002366194B8 (es) |
| BR (1) | BR0214221A (es) |
| CA (1) | CA2467551A1 (es) |
| DE (1) | DE60206652T2 (es) |
| ES (1) | ES2249639T3 (es) |
| GT (1) | GT200200233A (es) |
| MX (1) | MXPA04004683A (es) |
| PA (1) | PA8557901A1 (es) |
| PE (1) | PE20030715A1 (es) |
| PL (1) | PL369470A1 (es) |
| RU (1) | RU2295523C2 (es) |
| TW (1) | TW200407137A (es) |
| UY (1) | UY27543A1 (es) |
| WO (1) | WO2003043634A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| US6727247B2 (en) * | 2001-12-10 | 2004-04-27 | Hoffman-La Roche Inc. | Substituted benzothiazole amide derivatives |
| DK3473251T3 (da) | 2002-12-20 | 2024-01-22 | Niconovum Ab | Nikotin-cellulose-kombination |
| CA2539314A1 (en) * | 2003-09-19 | 2005-03-31 | F. Hoffmann-La Roche Ag | Thiazolopyridine derivatives as adenosine receptor ligands |
| US7714009B2 (en) | 2003-10-31 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| AU2005263499B2 (en) * | 2004-07-22 | 2010-11-25 | F. Hoffmann-La Roche Ag | Substituted benzothiazoles |
| MX2007000638A (es) * | 2004-07-22 | 2007-03-07 | Hoffmann La Roche | Derivados de benzotiazol. |
| ES2273599B1 (es) * | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| CA2646942C (en) | 2006-03-16 | 2014-07-29 | Niconovum Ab | Improved snuff composition |
| CA2665726C (en) * | 2006-10-11 | 2016-04-19 | Alpharma, Inc. | Pharmaceutical compositions |
| ES2398312T3 (es) * | 2007-04-04 | 2013-03-15 | Merck Sharp & Dohme Corp. | Agentes terapéuticos |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PT3393655T (pt) | 2015-12-22 | 2021-02-23 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| ES3029536T3 (en) | 2016-08-24 | 2025-06-24 | Zogenix International Ltd | Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US10517841B1 (en) * | 2018-06-14 | 2019-12-31 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| DE102019110904B4 (de) | 2019-04-26 | 2022-01-20 | Helmholtz-Zentrum Dresden - Rossendorf E. V. | N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3374550D1 (en) | 1982-12-21 | 1987-12-23 | Johnsen Jorgensen Plastics Ltd | Dispensing container |
| IL90337A0 (en) * | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
| CA2413086C (en) * | 2000-06-21 | 2011-06-28 | Alexander Alanine | Benzothiazole derivatives |
-
2002
- 2002-11-05 US US10/288,531 patent/US6599901B1/en not_active Expired - Fee Related
- 2002-11-09 CN CNB028228901A patent/CN100346792C/zh not_active Expired - Fee Related
- 2002-11-09 KR KR1020047007646A patent/KR100577109B1/ko not_active Expired - Fee Related
- 2002-11-09 BR BR0214221-0A patent/BR0214221A/pt not_active IP Right Cessation
- 2002-11-09 CA CA002467551A patent/CA2467551A1/en not_active Abandoned
- 2002-11-09 AU AU2002366194A patent/AU2002366194B8/en not_active Ceased
- 2002-11-09 ES ES02803360T patent/ES2249639T3/es not_active Expired - Lifetime
- 2002-11-09 WO PCT/EP2002/012543 patent/WO2003043634A1/en not_active Ceased
- 2002-11-09 RU RU2004118423/04A patent/RU2295523C2/ru not_active IP Right Cessation
- 2002-11-09 JP JP2003545315A patent/JP4216192B2/ja not_active Expired - Fee Related
- 2002-11-09 MX MXPA04004683A patent/MXPA04004683A/es active IP Right Grant
- 2002-11-09 EP EP02803360A patent/EP1448196B1/en not_active Expired - Lifetime
- 2002-11-09 DE DE60206652T patent/DE60206652T2/de not_active Expired - Fee Related
- 2002-11-09 PL PL02369470A patent/PL369470A1/xx not_active Application Discontinuation
- 2002-11-09 AT AT02803360T patent/ATE306265T1/de not_active IP Right Cessation
- 2002-11-14 PA PA20028557901A patent/PA8557901A1/es unknown
- 2002-11-14 TW TW091133382A patent/TW200407137A/zh unknown
- 2002-11-15 AR ARP020104398A patent/AR037528A1/es not_active Application Discontinuation
- 2002-11-15 PE PE2002001103A patent/PE20030715A1/es not_active Application Discontinuation
- 2002-11-18 GT GT200200233A patent/GT200200233A/es unknown
- 2002-11-18 UY UY27543A patent/UY27543A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1448196A1 (en) | 2004-08-25 |
| ATE306265T1 (de) | 2005-10-15 |
| RU2004118423A (ru) | 2006-01-10 |
| EP1448196B1 (en) | 2005-10-12 |
| AU2002366194B8 (en) | 2006-11-16 |
| MXPA04004683A (es) | 2004-08-12 |
| PA8557901A1 (es) | 2003-06-30 |
| PE20030715A1 (es) | 2003-08-29 |
| KR100577109B1 (ko) | 2006-05-10 |
| JP4216192B2 (ja) | 2009-01-28 |
| DE60206652D1 (de) | 2006-02-23 |
| AU2002366194A1 (en) | 2003-06-10 |
| CN1589146A (zh) | 2005-03-02 |
| US6599901B1 (en) | 2003-07-29 |
| AU2002366194B2 (en) | 2006-10-26 |
| GT200200233A (es) | 2003-06-17 |
| CA2467551A1 (en) | 2003-05-30 |
| KR20050044537A (ko) | 2005-05-12 |
| RU2295523C2 (ru) | 2007-03-20 |
| UY27543A1 (es) | 2003-05-30 |
| DE60206652T2 (de) | 2006-06-22 |
| CN100346792C (zh) | 2007-11-07 |
| BR0214221A (pt) | 2004-09-21 |
| PL369470A1 (en) | 2005-04-18 |
| TW200407137A (en) | 2004-05-16 |
| ES2249639T3 (es) | 2006-04-01 |
| WO2003043634A1 (en) | 2003-05-30 |
| JP2005515980A (ja) | 2005-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037528A1 (es) | Derivados de piridona de benzotiazol | |
| YU96502A (sh) | Derivati benzotiazola | |
| BR0108611A (pt) | Moduladores de receptor de adenosina | |
| GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
| DK0975595T3 (da) | Kokainanaloger | |
| SE0104334D0 (sv) | Therapeutic agents | |
| AR039367A1 (es) | Compuestos derivados de benzotiazol, nicotina o isonicotina, un proceso para su preparacion, un medicamento que los contiene y uso de los mismos | |
| BRPI0414266A (pt) | derivados de tiazolopiridina como ligandos receptores da adenosina | |
| WO2007066149A3 (en) | Topical pharmaceutical compositions | |
| DE69333387D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Norastemizol. | |
| ECSP067018A (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico | |
| AR037457A1 (es) | Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| AR037221A1 (es) | Compuestos derivados de piridina, uso de los mismos, un procedimiento para su preparacion y un medicamento que contiene uno o mas de dichos compuestos | |
| BRPI0409308A (pt) | derivados azabiciclo como antagonistas de receptores muscarìnicos, composição farmacêutica e processo para sua preparação | |
| BRPI0513511A (pt) | derivados de benzotiazol | |
| AR049998A1 (es) | BENZOTIAZOLES SUSTITUIDOS COMO LIGANDOS DEL RECEPTOR DE ADENOSINA, PROCESO DE PREPARACIoN Y SU USO | |
| AR037792A1 (es) | Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen | |
| DK121789A (da) | 4,5,6,7-tetrahydroisothiazole oe4,5-caapyridinderivater | |
| BR0309025A (pt) | Agentes antidiabéticos | |
| MA28026A1 (fr) | Thiénoimidazoles substitués, procédé de production et utilisation de ceux-ci comme médicament ou agent de diagnostic, et médicaments les comprenant | |
| UY27574A1 (es) | Uso de ureas de benzotiazoles | |
| WO2006071603A3 (en) | Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure | |
| AR037791A1 (es) | Compuestos derivados de benzotiofeno, su empleo, un procedimiento para prepararlos y medicamentos que los contienen | |
| ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria | |
| BRPI0410664A (pt) | derivados de benzopirano substituìdos com um derivado de tioxobenzoxazole, sais farmaceuticamente aceitáveis destes, suas preparações e composições farmacêuticas contendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |